This document is a Japanese translation of the original English press release issued on February 3, 2025 (US local time) by Pfizer Inc, with whom Ono Pharmaceutical Co., Ltd. has a license agreement on BRAFTOVI®. Please note that the original English text takes precedence over the contents of the Japanese translation. Please see the following link for the original English press release: https://investors.pfizer.com/investor-news/default.aspx .

NOTE:
 On December 12, 2024, Ono Pharmaceutical Co., Ltd. submitted a supplemental application for BRAFTOVI® (generic name: encorafenib) Capsule, a BRAF inhibitor, in combination with cetuximab, an anti-human EGFR monoclonal antibody, and chemotherapy in Japan for the indication of “unresectable, advanced or recurrent colorectal cancer with BRAF-mutation”.